Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 290

1.

Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

Niles J.

Clin Exp Immunol. 2011 May;164 Suppl 1:27-30. doi: 10.1111/j.1365-2249.2011.04363.x. Review.

2.

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.

Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X.

Autoimmun Rev. 2012 Jul;11(9):646-52. doi: 10.1016/j.autrev.2011.11.007. Epub 2011 Nov 21. Review.

PMID:
22146313
3.

Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis?

Tarzi R, Pusey C.

Nat Rev Nephrol. 2013 Nov;9(11):628-9. doi: 10.1038/nrneph.2013.204. Epub 2013 Oct 1.

PMID:
24080801
4.

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.

Rheumatology (Oxford). 2006 Nov;45(11):1432-6. Epub 2006 Apr 21.

5.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.

J Am Soc Nephrol. 2015 Apr;26(4):976-85. doi: 10.1681/ASN.2014010046. Epub 2014 Nov 7.

6.

Advances in therapy for ANCA-associated vasculitis.

Geetha D, Seo P.

Curr Rheumatol Rep. 2012 Dec;14(6):509-15. doi: 10.1007/s11926-012-0284-0. Review.

PMID:
22895899
8.

[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].

Roccatello D, Vangelista A, Pani A.

G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. Review. Italian.

PMID:
22028261
9.

Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.

Wendt M, Gunnarsson I, Bratt J, Bruchfeld A.

Scand J Rheumatol. 2012 Mar;41(2):116-9. doi: 10.3109/03009742.2011.620573. Epub 2011 Nov 28.

PMID:
22118245
10.

Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.

Timlin H, Lee SM, Manno RL, Seo P, Geetha D.

Semin Arthritis Rheum. 2015 Aug;45(1):67-9. doi: 10.1016/j.semarthrit.2015.02.005. Epub 2015 Feb 20.

11.

S2. Rituximab for ANCA-associated vasculitis: the UK experience.

Jayne D.

Presse Med. 2013 Apr;42(4 Pt 2):532-4. doi: 10.1016/j.lpm.2013.01.049. Epub 2013 Mar 9. Review. No abstract available.

PMID:
23490639
12.

Rituximab in ANCA-associated vasculitis: fad or fact?

Fervenza FC.

Nephron Clin Pract. 2011;118(2):c182-8; discussion c188. doi: 10.1159/000321437. Epub 2010 Dec 16. Review.

13.

[Renal disease in ANCA-associated vasculitis].

Vanhille P, Vrigneaud L, Quéméneur T.

Presse Med. 2012 Mar;41(3 Pt 1):247-53. doi: 10.1016/j.lpm.2011.11.009. Epub 2012 Jan 21. Review. French.

PMID:
22265953
14.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.

Cartin-Ceba R, Fervenza FC, Specks U.

Curr Opin Rheumatol. 2012 Jan;24(1):15-23. doi: 10.1097/BOR.0b013e32834d5730. Review.

PMID:
22089095
15.

[Diagnosis and management of small vessel vasculitides].

Pettersson T, Karjalainen A.

Duodecim. 2010;126(12):1496-507. Review. Finnish.

PMID:
20617753
16.

Vasculitis: Rituximab: effective in ANCA-associated vasculitis?

Schönermarck U, de Groot K.

Nat Rev Nephrol. 2011 Jan;7(1):6-8. doi: 10.1038/nrneph.2010.167. No abstract available.

PMID:
21173754
17.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.

Santana AN, Woronik V, Halpern AS, Barbas CS.

J Bras Pneumol. 2011 Nov-Dec;37(6):809-16. Review. English, Portuguese.

18.

Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: rituximab may be the right choice?

Szilasi M, Mátyus J, File I, Szücs G, Rákóczi E, Pfliegler G, Szabó Z, Végh E, Szekanecz Z.

Autoimmunity. 2012 Jun;45(4):304-9. doi: 10.3109/08916934.2012.677078. Epub 2012 Apr 10.

PMID:
22443800
19.

Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis.

De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD.

Am J Kidney Dis. 1995 Mar;25(3):380-9.

PMID:
7872315
20.

Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?

Kronbichler A, Jayne DR.

Nephrol Dial Transplant. 2015 Jul;30(7):1075-81. doi: 10.1093/ndt/gfv216. Epub 2015 May 21.

PMID:
25999374
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk